Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.
- Andreas H Groll,
- Robert Townsend,
- Amit Desai,
- Nkechi Azie,
- Mark Jones,
- Marc Engelhardt,
- Anne-Hortense Schmitt-Hoffman,
- Robert J Brüggemann
Transpl Infect Dis 2017 Jul 19. Epub 2017 Jul 19.
Department of Pharmacy, Radboud University Nijmegen Medical Centre and Centre of Expertise in Mycology Radboud UMC/CWZ, Nijmegen, The Netherlands.
Patients undergoing treatment with immunosuppressant drugs following solid organ or hematopoietic stem cell transplantation are at particular risk for development of serious infections such as invasive aspergillosis. Four triazole antifungal drugs, voriconazole, posaconazole, itraconazole, and isavuconazole, are approved to treat invasive aspergillosis either as first- or second-line therapy. All of these agents are inhibitors of cytochrome P450 3A4, which plays a key role in metabolizing immunosuppressant drugs such as cyclosporine, tacrolimus, and sirolimus. Read More